Last reviewed · How we verify
RSVpreF Vaccine (rsvpref-vaccine)
The RSVpreF Vaccine, developed by Pfizer Inc., is a marketed drug that prevents severe lower respiratory tract disease caused by RSV in high-risk infants. It has undergone 26 clinical trials and has been the subject of 81 publications. The vaccine's commercial significance lies in its ability to address a critical public health need. However, its revenue figures are not publicly available. The vaccine's mechanism of action is not explicitly stated. Its key indication is the prevention of RSV-associated hospitalization in high-risk infants. The vaccine's clinical differentiation lies in its ability to provide protection against severe RSV disease. The vaccine's pipeline developments are not specified.
At a glance
| Generic name | rsvpref-vaccine |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | vaccine |
| Target | RSV |
| Modality | Vaccine |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV-associated hospitalization due to prematurity.
- Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in young children with a history of premature birth or bronchopulmonary dysplasia.
Common side effects
Drug interactions
- Live, attenuated influenza vaccines
- Live, attenuated varicella vaccine
- Live, attenuated MMR vaccine
- Live, attenuated yellow fever vaccine
- Live, attenuated typhoid vaccine
- Live, attenuated rotavirus vaccine
- Live, attenuated nasal influenza vaccine
- Live, attenuated oral poliovirus vaccine
- Live, attenuated oral typhoid vaccine
- Live, attenuated oral rotavirus vaccine
- Live, attenuated oral human papillomavirus vaccine
- Live, attenuated nasal influenza vaccine
Key clinical trials
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products (PHASE4)
- A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose (PHASE3)
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy (PHASE4)
- TARSILA Real-World Evidence Study
- A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea (PHASE3)
- SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER
- Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (PHASE3)
- RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSVpreF Vaccine CI brief — competitive landscape report
- RSVpreF Vaccine updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI